These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 31853575)
1. Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma. Tsukahara T; Watanabe K; Murata K; Takahashi A; Mizushima E; Shibayama Y; Kameshima H; Hatae R; Ohno Y; Kawahara R; Murai A; Nakatsugawa M; Kubo T; Kanaseki T; Hirohashi Y; Terui T; Asanuma H; Hasegawa T; Sato N; Torigoe T Cancer Immunol Immunother; 2020 Feb; 69(2):189-197. PubMed ID: 31853575 [TBL] [Abstract][Full Text] [Related]
2. Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial. Legat A; Maby-El Hajjami H; Baumgaertner P; Cagnon L; Abed Maillard S; Geldhof C; Iancu EM; Lebon L; Guillaume P; Dojcinovic D; Michielin O; Romano E; Berthod G; Rimoldi D; Triebel F; Luescher I; Rufer N; Speiser DE Clin Cancer Res; 2016 Mar; 22(6):1330-40. PubMed ID: 26500235 [TBL] [Abstract][Full Text] [Related]
3. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U Front Immunol; 2020; 11():895. PubMed ID: 32528470 [TBL] [Abstract][Full Text] [Related]
5. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ Front Immunol; 2019; 10():1939. PubMed ID: 31475002 [TBL] [Abstract][Full Text] [Related]
6. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230 [TBL] [Abstract][Full Text] [Related]
9. The adjuvant effect of melanin is superior to incomplete Freund's adjuvant in subunit/peptide vaccines in mice. Cuzzubbo S; Banissi C; Rouchon MS; Tran T; Tanchot C; Tartour E; Carpentier AF Cancer Immunol Immunother; 2020 Dec; 69(12):2501-2512. PubMed ID: 32561966 [TBL] [Abstract][Full Text] [Related]
10. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. Anghileri E; Di Ianni N; Paterra R; Langella T; Zhao J; Eoli M; Patanè M; Pollo B; Cuccarini V; Iavarone A; Rabadan R; Finocchiaro G; Pellegatta S Cancer Immunol Immunother; 2021 Mar; 70(3):831-842. PubMed ID: 33140187 [TBL] [Abstract][Full Text] [Related]
11. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030 [TBL] [Abstract][Full Text] [Related]
12. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296 [TBL] [Abstract][Full Text] [Related]
13. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324 [TBL] [Abstract][Full Text] [Related]
14. [Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Yoshimatsu K; Yokomizo H; Osawa G; Fujimoto T; Otani T; Tsunoda T; Nakamura Y; Ogawa K Gan To Kagaku Ryoho; 2008 Nov; 35(12):2268-70. PubMed ID: 19106592 [TBL] [Abstract][Full Text] [Related]
15. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide. Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225 [TBL] [Abstract][Full Text] [Related]
16. 5-Aminolevulinic acid tumor paint and photodynamic therapy for myxofibrosarcoma: an in vitro study. Kenan S; Liang H; Goodman HJ; Jacobs AJ; Chan A; Grande DA; Levin AS J Orthop Surg Res; 2020 Mar; 15(1):94. PubMed ID: 32138774 [TBL] [Abstract][Full Text] [Related]
17. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239 [TBL] [Abstract][Full Text] [Related]
18. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report. Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S Front Immunol; 2018; 9():1769. PubMed ID: 30108590 [TBL] [Abstract][Full Text] [Related]
19. Development of T cell receptor-engineered T cells targeting the sarcoma-associated antigen papillomavirus binding factor. Hamada S; Tsukahara T; Watanabe Y; Murata K; Mizue Y; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Nakatsugawa M; Teramoto A; Yamashita T; Torigoe T Cancer Sci; 2024 Jan; 115(1):24-35. PubMed ID: 37879364 [TBL] [Abstract][Full Text] [Related]
20. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series. Kubo T; Tsurita G; Hirohashi Y; Yasui H; Ota Y; Watanabe K; Murai A; Matsuo K; Asanuma H; Shima H; Wada S; Nakatsugawa M; Kanaseki T; Tsukahara T; Mizuguchi T; Hirata K; Takemasa I; Imai K; Sato N; Torigoe T Cancer Sci; 2019 Aug; 110(8):2386-2395. PubMed ID: 31206934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]